These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6383871)

  • 1. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
    Creese I; Sibley DR; Leff SE
    Fed Proc; 1984 Oct; 43(13):2779-84. PubMed ID: 6383871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
    Enjalbert A; Bockaert J
    Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
    Lin C; McGonigle P; Molinoff PB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):950-6. PubMed ID: 2958621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay of dopamine receptors with [alpha-3H]flupenthixol.
    Huff RM; Molinoff PB
    J Pharmacol Exp Ther; 1985 Jan; 232(1):57-61. PubMed ID: 3965700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites.
    Severson JA; Randall PK
    J Pharmacol Exp Ther; 1985 May; 233(2):361-8. PubMed ID: 3158731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE; Hamblin MW; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):171-83. PubMed ID: 3969066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioligand binding studies: evidence for multiple dopamine receptors.
    Creese I; Sibley DR
    Commun Psychopharmacol; 1979; 3(6):385-95. PubMed ID: 546587
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine receptor binding of a novel dibenzodioxazocine derivative, EGYT-2509.
    Gyüre K; Szentendrei T; Kanyicska B; Fekete MI; Rónai AZ
    Pol J Pharmacol Pharm; 1985; 37(3):253-61. PubMed ID: 2866498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation by protein kinase C modulates agonist binding to striatal dopamine D2 receptors.
    Rogue P; Zwiller J; Malviya AN; Vincendon G
    Biochem Int; 1990 Nov; 22(3):575-82. PubMed ID: 1981673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
    Zahniser NR; Dubocovich ML
    J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR; Creese I
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
    Munemura M; Agui T; Sibley DR
    Endocrinology; 1989 Jan; 124(1):346-55. PubMed ID: 2521206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR; Molinoff PB
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide.
    Wreggett KA; Seeman P
    Mol Pharmacol; 1984 Jan; 25(1):10-7. PubMed ID: 6231467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
    Seiler MP; Markstein R
    Mol Pharmacol; 1982 Sep; 22(2):281-9. PubMed ID: 7144729
    [No Abstract]   [Full Text] [Related]  

  • 17. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
    Hamblin MW; Creese I
    Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of alpha- and beta-rotameric forms of 2-substituted octahydrobenzo[f]quinoline dopamine congeners with high and low affinity states of the anterior pituitary dopamine receptor and prolactin inhibition.
    Findell PR; Torkelson SM; Craig JC; Weiner RI
    Mol Pharmacol; 1988 Jan; 33(1):78-83. PubMed ID: 3336350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]spiroperidol identifies a D-2 dopamine receptor inhibiting adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.
    Frey EA; Cote TE; Grewe CW; Kebabian JW
    Endocrinology; 1982 Jun; 110(6):1897-904. PubMed ID: 7075543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state.
    Sibley DR; Mahan LC; Creese I
    Mol Pharmacol; 1983 Mar; 23(2):295-302. PubMed ID: 6835198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.